Regulatory
Advocates Seek to Elevate FDA Patient Access Program
FDA needs to expand and empower its Office of Health & Constituent Affairs and its Patient Liaison Program to better coordinate interactions with individuals and physicians seeking expedited access to experimental therapies, writes Jill Wechsler
...Read more |
Pharmaceutical Executive E-Book – Coming November 2015: Securing the Global Supply Chain: Strategies for Operational Excellence
Key Topics include:
- Compliance Groundswell: What are the New Rules and Regulator Expectations?
- Global Dynamics of Risk: Can Technology Keep Pace?
- Benchmarking Best Practices: Upgrading Company Performance Culture
- What's Ahead: How Logistics and Distribution Science will Shape Tomorrow's Supply Chain
 Contact your sales rep for more information and to secure your sponsorship. |
Recruitment
Attracting the Ideal Millennial Workforce
The key to success in the modern pharma era is engaging a workforce that's flexible enough to keep pace with evolving needs. That's where contingent labor comes in, writes Rebecca Cenni
...Read more |
Pharmaceutical Executive E-Book – Coming October 2015: Changing Contours of Commercialization: Impact of US Health Reform on Patients, Payers and Providers
Key Topics include:
- Phase-in of the 2010 Affordable Care Act: Five stages of pain and plenty
- Pay for Performance and Shared Savings Programs – Implications for Pharma Marketers
- How ACO models are driving physician and provider decision-making
- Primer on policies and financial drivers impacting payer markets – MLR, MSSP, CMS etc.
 Contact your sales rep for more information and to secure your sponsorship. |
Europe
The “Seasoned Biotech CEO”: A Rare Commodity
A recent survey of European biopharma companies and board members revealed that 80 percent of firms find access to qualified senior executives to be a challenge, with the toughest spot to fill being the "seasoned CEO"
...Read more |
Patient adherence in Germany - benefit vs. cost-containment
On demand
Join Joanne Thiele, Market Access Project Manager from Quintiles Germany and Hans Holger Bleβ, Director of Health Services Research department at IGES Institut GmbH as they discuss the importance of patient adherence programs in Germany.
 Learn more |
Comment
The Market Access Timing Dilemma
The news that immunotherapy drug Opdivo (nivolumab, BMS) will not be available to UK lung cancer patients until May 2016 (after a NICE cost-effectiveness review) highlights how timing is a dilemma when considering market access for prescription drugs. Ed Schoonveld reports
...Read more |
Comment
2015 Medicaid Drug Price Controls: A 1980s Throwback?
Reading the various reports of the Rx industry jousting with state Medicaid programs that are struggling with the costs of the new Hep C, hypertension, MS, cancer, and other “specialty drugs”, Tom Norton can't help but think about that old adage: The Past is Prologue
...Read more |
 |
 //Immunomedics (Morris Plain, NJ) announced the appointment of Arthur S. Kirsch to its Board of Directors. //Radius Health (Waltham, MA) elected Catherine Friedman, former Co-Head of the Biotechnology Practice at Morgan Stanley, to its Board of Directors. //Technology company Sanguine (Los Angeles, CA) hired Susan Aroyan as Chief Strategy Officer. //Cloud Pharmaceuticals (Research Triangle Park, NC) appointed Lyle Lohmeyer as CFO and Don Van Dyke as COO. // |
|
|
